See the latest news and media coverage for RedHill. We track all announcements, press releases, and industry mentions in real time, all in one place.
Specialty pharmaceutical company
redhillbio.comLast updated
In short: RedHill regained Nasdaq compliance, secured a $10.9 million legal judgment, and advanced opaganib for Ebola and various cancer types.
The transaction secures immediate capital and future milestone payments to fund strategic growth opportunities and accelerate operational profitability.
Cases and deaths have increased substantially; partnership discussions are ongoing with African agencies and Ugandan authorities.
$6 million upfront with potential $13.4 million from warrants for product acquisition and working capital.
The designation adds to existing orphan drug status for neuroblastoma and offers development incentives including a Priority Review Voucher.
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the divestment of its Talicia business to a subsidiary of...
These findings will be presented in an oral session (Abstract #5005) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. • In...
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided an update on the development of opaganib1 for Ebola virus...
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced private placement for the...
Track RedHill and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to RedHill and other trending companies.